- Home
- CSR vs PRAX Comparison
CSR vs PRAX Comparison
Compare CSR & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSR
- PRAX
- Stock Information
- Founded
- CSR 1970
- PRAX 2015
- Country
- CSR United States
- PRAX United States
- Employees
- CSR N/A
- PRAX N/A
- Industry
- CSR Real Estate Investment Trusts
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- CSR Real Estate
- PRAX Health Care
- Exchange
- CSR Nasdaq
- PRAX Nasdaq
- Market Cap
- CSR 997.0M
- PRAX 950.8M
- IPO Year
- CSR N/A
- PRAX 2020
- Fundamental
- Price
- CSR $60.52
- PRAX $46.85
- Analyst Decision
- CSR Buy
- PRAX Strong Buy
- Analyst Count
- CSR 7
- PRAX 9
- Target Price
- CSR $70.00
- PRAX $94.44
- AVG Volume (30 Days)
- CSR 98.4K
- PRAX 388.4K
- Earning Date
- CSR 10-27-2025
- PRAX 08-04-2025
- Dividend Yield
- CSR 5.16%
- PRAX N/A
- EPS Growth
- CSR N/A
- PRAX N/A
- EPS
- CSR N/A
- PRAX N/A
- Revenue
- CSR $267,076,000.00
- PRAX $7,765,000.00
- Revenue This Year
- CSR $5.37
- PRAX N/A
- Revenue Next Year
- CSR $3.01
- PRAX $25.00
- P/E Ratio
- CSR N/A
- PRAX N/A
- Revenue Growth
- CSR 3.44
- PRAX 338.45
- 52 Week Low
- CSR $52.76
- PRAX $26.70
- 52 Week High
- CSR $76.16
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- CSR 65.77
- PRAX 47.63
- Support Level
- CSR $57.07
- PRAX $44.13
- Resistance Level
- CSR $59.68
- PRAX $47.06
- Average True Range (ATR)
- CSR 1.17
- PRAX 2.18
- MACD
- CSR 0.51
- PRAX 0.05
- Stochastic Oscillator
- CSR 93.18
- PRAX 54.73
About CSR D/B/A Centerspace
Centerspace is a real estate investment trust (REIT) that focuses on the ownership, management, acquisitions, redevelopment, and development of apartment communities. The company operates through a single reportable segment which includes the ownership, management, development, redevelopment, and acquisition of apartment communities and conduct their corporate operations from offices in Minot, North Dakota and Minneapolis, Minnesota.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.